

# **CIRCULATING TUMOR CELLS**

---

## **Isolation and Analysis**

Edited by

**Z. HUGH FAN**

**WILEY**

# CONTENTS

<b>List of Contributors</b>	<b>xv</b>
<b>Foreword</b>	<b>xxi</b>
<b>Preface</b>	<b>xxv</b>
<b>PART I INTRODUCTION</b>	<b>1</b>
<b>1 Circulating Tumor Cells and Historic Perspectives</b>	<b>3</b>
<i>Jonathan W. Uhr</i>	
1.1 Early Studies on Cancer Dormancy Led to the Development of a Sensitive Assay for CTCs (1970–1998)	3
1.2 Modern Era for Counting CTCs: 1998–2007	6
1.3 Proof of Malignancy of CTCs	7
1.4 New Experiments Involving CTCs	7
1.5 Clinical Cancer Dormancy	8
1.6 Human Epidermal Growth Factor Receptor 2 (HER2) Gene Amplification can be Acquired as Breast Cancer Progresses	10
1.7 uPAR and HER2 Co-amplification	11
1.8 Epithelial–Mesenchymal Transition (EMT)	12
1.9 New Instruments to Capture CTCs	14
1.10 Genotypic Analyses	15
1.11 Conclusions	18
References	20

<b>2</b>	<b>Introduction to Microfluidic</b>	<b>33</b>
	<i>Kangfu Chen and Z. Hugh Fan</i>	
2.1	Introduction	33
2.1.1	Brief History	33
2.1.2	Fluids	34
2.1.3	Microfluidic	34
2.1.4	Advantages of Microfluidic	35
2.2	Scaling Law	36
2.2.1	Laminar Flow	36
2.2.2	Flow Rate	37
2.2.3	Diffusion	38
2.3	Device Fabrication	39
2.3.1	Materials	39
2.3.2	Fabrication Methods	40
2.3.2.1	Photolithography	40
2.3.2.2	Etching	41
2.3.2.3	Bonding	42
2.3.2.4	Molding	42
2.4	Functional Components in Microfluidic Devices	43
2.4.1	Micropumps	43
2.4.1.1	Mechanical Pumps	43
2.4.1.2	Nonmechanical Pumps	44
2.4.2	Microvalves	44
2.4.3	Micromixers	45
2.4.4	Other Components	46
2.5	Concluding Remarks	46
	References	47
<b>PART II</b>	<b>ISOLATION METHODS</b>	<b>51</b>
<b>3</b>	<b>Ensemble-decision Aliquot Ranking (eDAR) for CTC Isolation and Analysis</b>	<b>53</b>
	<i>Mengxia Zhao, Perry G. Schiro, and Daniel T. Chiu</i>	
3.1	Overview of eDAR	53
3.2	Individual Components and Analytical Performance of eDAR	55
3.2.1	Aliquot Ranking	55
3.2.2	Aliquot Sorting	59
3.2.2.1	Active Sorting Scheme Based on an On-Chip Solenoid	59
3.2.2.2	Active Sorting Scheme Based on an Off-Chip Solenoid	60
3.2.3	On-Chip Purification	63
3.2.3.1	Purification via Integrated Planar Filter	63
3.2.3.2	Purification via Microfabricated Slits	64

3.2.4	Secondary Labeling and the Enumeration of CTCs	65
3.2.5	Characterization and Analytical Performance of eDAR	67
3.3	Application and Downstream Analyses of eDAR	69
3.3.1	Enumeration of CTCs from Cancer Patients using eDAR	69
3.3.2	Downstream Analysis of CTCs Isolated by eDAR	71
3.3.3	Automated High-Throughput Counting of CTCs – A “Simplified Version of eDAR	75
3.4	Conclusion and Perspective	80
	References	81
<b>4</b>	<b>Sinusoidal Microchannels with High Aspect Ratios for CTC Selection and Analysis</b>	<b>85</b>
	<i>Joshua M. Jackson, Małgorzata A. Witek, and Steven A. Soper</i>	
4.1	Introduction	85
4.1.1	Brief Perspective	85
4.1.2	Overview of CTC Selection Modalities and Assay Metrics	87
4.2	Parallel Arrays of High-Aspect-Ratio, Sinusoidal Microchannels for CTC Selection	90
4.2.1	Production of CTC <i>In Vitro</i> Diagnostic Devices in Thermoplastics	91
4.2.2	Activation of High-Aspect-Ratio Microchannels for Efficient Ab Immobilization	94
4.2.3	CTC Selection in Sinusoidal Microchannels from a Fluid Dynamics Perspective	99
4.2.3.1	Centrifugal Forces in Curved Microchannels	100
4.2.3.2	Transient Dynamics of CTC-Ab Binding	104
4.2.4	Parallel Arrays for High-Throughput Sample Processing	107
4.3	Clinical Applications of Sinusoidal CTC Microchip	114
4.4	Conclusion	118
	Acknowledgments	119
	References	119
<b>5</b>	<b>Cell Separation using Inertial Microfluidic</b>	<b>127</b>
	<i>Nivedita Nivedita and Ian Papautsky</i>	
5.1	Introduction	127
5.2	Device Fabrication and System Setup	128
5.3	Inertial Focusing in Microfluidic	129
5.4	Cancer Cell Separation in Straight Microchannels	132
5.5	Cancer Cell Separation in Spiral Microchannels	136
5.6	Conclusions	142
	References	142

<b>6</b>	<b>Morphological Characteristics of CTCs and the Potential for Deformability-Based Separation</b>	<b>147</b>
	<i>Simon P. Duffy and Hongshen Ma</i>	
6.1	Introduction	147
6.2	Limitations of Antibody-based CTC Separation Methods	148
6.3	Morphological and Biophysical Differences Between CTCs and Hematological Cells	149
6.4	Historical and Recent Methods in CTC Separation Based on Biophysical Properties	153
6.5	Microfluidic Ratchet for Deformability-Based Separation of CTCs	155
	6.5.1 Microfluidic Ratchet Mechanism	155
	6.5.2 Design of the Microfluidic Ratchet	156
	6.5.3 Validation of the Microfluidic Ratchet Mechanism	158
	6.5.4 Viability of Cells Enriched by the Microfluidic Ratchet Mechanism	159
6.6	Resettable Cell Trap for Deformability-based Separation of CTCs	160
	6.6.1 Resettable Cell Trap Mechanism	160
	6.6.2 Validation of the Resettable Cell Trap Device	163
	6.6.3 Application of the Resettable Cell Trap for CTC Enrichment	164
6.7	Summary	165
	References	166
<b>7</b>	<b>Microfabricated Filter Membranes for Capture and Characterization of Circulating Tumor Cells (CTCs)</b>	<b>173</b>
	<i>Zheng Ao, Richard J. Cote, Ram H. Datar, and Anthony Williams</i>	
7.1	Introduction	173
7.2	Size-based Enrichment of Circulating Tumor Cells	174
7.3	Comparison Between Size-based CTC Isolation and Affinity-based Isolation	177
7.4	Characterization of CTCs Captured by Microfilter	178
	7.4.1 Genomic Analysis of CTCs Enriched by Microfabricated Filter Membrane	178
	7.4.2 Gene Expression Analysis of CTC Enriched by Microfabricated Filter Membrane	179
	7.4.3 Functional Characterization of CTCs Enriched by Microfabricated Filter Membrane	180
7.5	Conclusion	180
	References	181

<b>8</b>	<b>Miniaturized Nuclear Magnetic Resonance Platform for Rare Cell Detection and Profilin</b>	<b>183</b>
	<i>Sangmoo Jeong, Changwook Min, Huilin Shao, Cesar M. Castro, Ralph Weissleder, and Hakho Lee</i>	
8.1	Introduction	183
8.2	$\mu$ NMR Technology	184
	8.2.1 Magnetic Nanoparticles with High Transverse Relaxivity	185
	8.2.2 Bioorthogonal Strategy for Efficient MNP Labeling	188
	8.2.3 Miniaturized NMR Probe	188
8.3	Clinical Application of $\mu$ NMR for CTC Detection and Profilin	191
	8.3.1 Quad-Marker Assay Integrated with $\mu$ NMR	192
	8.3.2 Comparison of Biomarkers in CTC and Bulk Tumor Cell	192
8.4	Conclusion	196
	References	196
<b>9</b>	<b>Nanovelcro Cell-Affinity Assay for Detecting and Characterizing Circulating Tumor Cells</b>	<b>201</b>
	<i>Millicent Lin, Anna Fong, Sharon Chen, Yang Zhang, Jie-fu Chen, Paulina Do, Morgan Fong, Shang-Fu Chen, Pauline Yang, An-Jou Liang, Qingyu Li, Min Song, Shuang Hou, and Hsian-Rong Tseng</i>	
9.1	Introduction	202
	9.1.1 Circulating Tumor Cells	202
	9.1.2 Current CTC Capture Methods	202
	9.1.3 The Evolution of NanoVelcro Cell-Affinity Assays	205
	9.1.4 Nanostructured Substrates for Cell Biology	206
9.2	Proof-of-Concept Demonstration of NanoVelcro Cell-Affinity Substrates	207
	9.2.1 Stationary NanoVelcro CTC Assay	207
	9.2.2 General Applicability of NanoVelcro CTC Substrates	207
9.3	First-Generation NanoVelcro Chips for CTC Enumeration	209
	9.3.1 Device Configuration of First-Generation NanoVelcro Chips	209
	9.3.2 Clinical Utility of First-Generation NanoVelcro Chips	212
	9.3.3 An Alternative Capture Agent, Aptamer	213
9.4	Second-Generation NanoVelcro-LMD Technology for Single CTC Isolation	214
	9.4.1 Preparation of PLGA NanoVelcro Chips	215
	9.4.2 NanoVelcro-LMD Technology and Mutational Analysis	215
	9.4.3 NanoVelcro-LCM Technology and Whole Exome Sequencing	215

9.5	Third-Generation Thermoresponsive NanoVelcro Chips	219
9.6	Conclusions and Future Perspectives	220
	Acknowledgment	221
	References	221
<b>10</b>	<b>Acoustophoresis in Tumor Cell Enrichment</b>	<b>227</b>
	<i>Per Augustsson, Cecilia Magnusson, Hans Lilja, and Thomas Laurell</i>	
10.1	Introduction	227
	10.1.1 Background	227
	10.1.2 System Specificatio	229
10.2	Factors Determining Acoustophoresis Cell Separation	230
	10.2.1 Acoustic Field	231
	10.2.2 Acoustic Radiation Force	231
	10.2.3 Trajectory of a Cell	232
	10.2.4 The Microchannel Flow Profil	233
10.3	Acoustophoresis System for Separating Cells	234
	10.3.1 Acoustophoresis Chip	234
	10.3.2 Actuation of Ultrasound	234
	10.3.3 Flow System	234
	10.3.4 Sample Preparation and Analysis	236
	10.3.4.1 Blood and Cancer Cell Preparation	236
	10.3.4.2 Cell Labeling	236
	10.3.5 Device Testing	237
	10.3.5.1 Varying the Flow Rate	237
	10.3.5.2 Cancer Cell Number	237
	10.3.5.3 Cancer Cell Diversity	237
10.4	Acoustophoresis Platform for Clinical Sample Processing	239
	10.4.1 The Acoustophoresis Chip	239
	10.4.2 Flow System	241
	10.4.2.1 Pressure-Driven Flow	241
	10.4.2.2 Operation of the Flow System for Cell Separation	241
	10.4.3 Temperature Control System	242
	10.4.4 Software Interface	242
	10.4.5 System Calibration using Microbeads	243
	10.4.6 Cell Separations	244
10.5	Unperturbed Cell Survival and Phenotype after Microchip Acoustophoresis	244
10.6	Summary	246
	References	246
<b>11</b>	<b>Photoacoustic Flow Cytometry for Detection and Capture of Circulating Melanoma Cells</b>	<b>249</b>
	<i>John A. Viator, Benjamin S. Goldschmidt, Kiran Bhattacharyya, and Kyle Rood</i>	

11.1	Introduction	249
11.1.1	Biomedical Photoacoustics	251
11.1.2	Photoacoustic Flow Cytometry	251
11.2	Current Methods for Detection and Capture of CMCs	254
11.2.1	Two-Phase Flow for Cell Capture	255
11.2.2	Photoacoustic Flow Cytometer	256
11.2.3	Blood Sample Preparation	256
11.2.4	Capture Process	258
11.2.5	Results of CMC Capture Study	259
11.3	Discussion	259
11.3.1	Extension to Nonpigmented CTCs	260
11.4	Future Work	261
	References	262
<b>12</b>	<b>Selectin-Mediated Targeting of Circulating Tumor Cells for Isolation and Treatment</b>	<b>267</b>
	<i>Jocelyn R. Marshall and Michael R. King</i>	
12.1	Introduction	267
12.1.1	Selectin Adhesion	267
12.1.2	Circulating Tumor Cells	270
12.2	CTC Capture by E-selectin	271
12.3	Applications for E-selectin in Cancer Diagnosis and Treatment	273
12.3.1	E-Selectin Capture for Drug Efficacy Testing	273
12.3.2	E-Selectin for use in Targeted Cancer Therapy	274
12.4	Conclusions	278
	References	279
<b>13</b>	<b>Aptamer-Enabled Tumor Cell Isolation</b>	<b>287</b>
	<i>Jinling Zhang and Z. Hugh Fan</i>	
13.1	Introduction	287
13.2	Aptamers and their Biomedical Applications	288
13.2.1	Identification of Aptamers	288
13.2.2	Aptamers versus Antibodies	289
13.2.3	List of Aptamers	290
13.3	Aptamer-based Tumor Cell Isolation	290
13.3.1	Aptamers with Microfluidic	290
13.3.1.1	Device Designs	290
13.3.1.2	Surface Functionalization	293
13.3.1.3	Tumor Cell Isolation	293
13.3.1.4	Instrument Setup	293
13.3.2	Aptamers with Nanoparticles	294
13.3.3	Aptamers with Innovative Schemes	295
13.3.4	Aptamers for CTC Isolation	296
13.4	Conclusion and Outlook	297
	References	297



<b>14 Depletion of Normal Cells for CTC Enrichment</b>	<b>301</b>
<i>Jeffrey J. Chalmers, Maryam B. Lustberg, Clayton Deighan, Kyoung-Joo Jenny Park, Yongqi Wu, and Peter Amaya</i>	
14.1 Introduction	301
14.2 Estimates of Number and Type of Cells in Blood	302
14.3 Summary of Examples of Negative Depletion	303
14.3.1 Removal of RBCs	303
14.3.2 Removal of Normal Nucleated Cells	304
14.4 Types of Cells Observed After Depletion of Normal Cells	305
14.5 Incomplete Depletion of Normal Cells	305
14.6 Conclusion	310
References	311
<b>PART III POST-ISOLATION ANALYSIS AND CLINICAL TRANSLATION</b>	<b>313</b>
<b>15 Tumor Heterogeneity and Single-cell Analysis of CTCs</b>	<b>315</b>
<i>Evelyn K. Sigal and Stefanie S. Jeffrey</i>	
15.1 Introduction	315
15.2 Tumor Heterogeneity	316
15.3 Single-Cell Analysis of CTCs and CTC Heterogeneity	318
15.4 Gene Expression Analysis	319
15.5 Mutational Analysis	321
15.6 Conclusion: Clinical Implications and Future Perspectives	323
References	324
<b>16 Single-Cell Molecular Profile and Biophysical Assessment of Circulating Tumor Cells</b>	<b>329</b>
<i>Devalingam Mahalingam, Pawel Osmulski, Chiou-Miin Wang, Aaron M. Horning, Anna D. Louie, Chun-Lin Lin, Maria E. Gaczynska, and Chun-Liang Chen</i>	
16.1 Introduction	329
16.2 Methods	331
16.2.1 Single-Cell Molecular Profiling	331
16.2.1.1 High-Throughput Single-Cell qRT-PCR using Microfluidic BioMark™ HD	332
16.2.1.2 Single-Cell Transcriptome Analysis using Gene Expression Microarray	332
16.2.1.3 Single-Cell RNA-Seq	333
16.2.2 Probing Cellular Biophysical Properties of Single Cells	333
16.2.2.1 The Instruments for Biophysical Assessment of Single Cells	333
16.2.2.2 The Biophysical Parameters of Single Cells	336

16.3	CTC Applications	336
16.3.1	Single-cell Molecular Profiling of CTCs	336
16.3.2	Analysis of Nanomechanical Phenotypes of Single CTCs	341
16.4	Conclusions	342
	References	343
<b>17</b>	<b>Directing Circulating Tumor Cell Technologies Into Clinical Practice</b>	<b>351</b>
	<i>Benjamin P. Casavant, David Kosoff, and Joshua M. Lang</i>	
17.1	Introduction	351
17.2	Definin Biomarkers	352
17.2.1	Prognostic CTC Biomarkers	353
17.2.2	Predictive CTC Biomarkers	355
17.2.3	Pharmacodynamic CTC Biomarkers	355
17.2.4	Diagnostic CTC Biomarkers	356
17.2.5	Surrogate CTC Biomarkers	356
17.3	The Technology	356
17.3.1	Translated Technologies	357
17.4	Translating Technology	357
17.4.1	The Technology Side	358
17.4.2	The Clinic Side	360
17.5	Conclusions	360
	References	361
<b>PART IV</b>	<b>COMMERCIALIZATION</b>	<b>365</b>
<b>18</b>	<b>DEPArray™ Technology for Single CTC Analysis</b>	<b>367</b>
	<i>Farideh Z. Bischoff, Gianni Medoro, and Nicolò Manaresi</i>	
18.1	Challenges in Molecular Profiling of CTCs	367
18.2	DEPArray™ Technology Solution	368
18.3	DEPArray™ for Single Tumor Cell Analysis	369
18.4	Clinical Significance in Single CTC Profiling	373
18.5	Conclusion	374
	References	374
<b>19</b>	<b>CELLSEARCH® Instrument, Features, and Usage</b>	<b>377</b>
	<i>Denis A. Smirnov, Brad W. Foulk, Mark C. Connelly, and Robert T. McCormack</i>	
19.1	Introduction	377
19.2	Principles of CELLSEARCH®	379
19.3	EpCAM Density and CTC Capture	380

19.4	Clinical Applications of CELLSEARCH® CTCs	383
19.4.1	CTC Enumeration	383
19.4.2	Expanding Enumeration	384
19.4.3	CTC Enumeration and Clinical Utility	385
19.4.4	Characterization of CTCs using CELLSEARCH®	387
19.5	Beyond EpCAM Capture	390
19.6	Discussion	391
	References	394
 <b>PART V GLOSSARY</b>		<b>401</b>
<b>Circulating Tumor Cell Glossary</b>		<b>403</b>
<i>Jose I. Varillas and Z. Hugh Fan</i>		
 <b>Index</b>		<b>423</b>